

BBS-Bioactive Bone Substitutes Plc: Claims of the complementary patent application for the ARTEBONE® product have been approved in the USA

BBS-Bioactive Bone Substitutes Plc | Company Release | June 04, 2024 at 17:45:00 EEST

Claims of the complementary patent application for the ARTEBONE® product have been approved in the USA

Claims for BBS-Bioactive Bone Substitutes Plc's ("Company") complementary patent application for "A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION" have been approved in the United States. These claims are related to ARTEBONE®-product and its use in the treatment method.

The Company will notify the US patent office that it approves the decision. The patent office will grant the patent after the approval of the Company.

CEO Juliusz Rakowski: "This patent significantly supplements the patent protection of the ARTEBONE® bone substitute."

This is the second supplementary patent that the Company has applied for in the USA. Patents in the USA have previously been announced:

- January 11, 2022 US Patent for the Manufacture of ARTEBONE® product
- November 17, 2021 Claims of the patent application for the manufacturing of the ARTEBONE® product have been approved in the USA
- April 7, 2020 The patent regarding the product ARTEBONE® has been granted in the USA

For more information, please contact:

Juliusz Rakowski, CEO
+358 50 448 5132

juliusz.rakowski@bbs-artebone.fi

Certified Advisor:

Nordic Certified Adviser AB,
+46 70 551 67 29,

info@certifiedadviser.se

Distribution

Nasdaq Helsinki

<https://www.bbs-artebone.fi/>



Company Release
04 June 2024 17:45:00 EEST

BBS in brief

BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our first developed product, ARTEBONE® Paste, is in the final stages of the CE marking process to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ over 20 people.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi